Skip to content

Use of sirolimus in patients with primary idiopathic membranous nephropathy: a prospective randomized control trial

Use of sirolimus in patients with primary idiopathic membranous nephropathy: a prospective randomized control trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012212
Enrollment
Unknown
Registered
2017-08-01
Start date
2017-07-28
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic membranous nephropathy

Interventions

1:Cyclosporine
2:cyclosporine combined with sirolimus

Sponsors

Renal Division, Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-70 years; 2. diagnosed as idiopathic membranous nephropathy by renal biopsy; 3. corticosteroids and immunosuppressive agents were not received in the recent 3 months; 4. blood pressure <140/90mmHg; 5. proteinuria =3.5g/day and eGFR= 45ml/min /1.73m2, with at least 3-month treatment of maximum tolerance dasage of ACEI/ARB; 6. serum creatinie =133umol/L; 7. agree to sign informed consent

Exclusion criteria

Exclusion criteria: 1. any type of secondary membranous nephropathy by renal biopsy; 2. any other tyoe of kidney disease; 3. uncontrolled infection; 4. Interstitial pneumonia; 5. new onset of cadiovascular disease in recent 3 months; 6. severe liver disease, liver enzyme elevation is not higher than 3 times; 7. uncontrolled severe hypertension; 8. A new or recurring malignancy within 8.5 years; 9. peptic ulcer or active digestive tract bleeding; 10. severe autoimmune disease; 11. pregnancy, lactation or scheduled pregnancy; 12. expected survival was less than December; 13. other clinical studies are currently in progress; 14. do not agree to sign informed consent; 15. the researchers found other conditions unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
proteinuria;

Countries

China

Contacts

Public ContactMinghui Zhao

Renal Division, Peking University First Hospital

mhzhao@bjmu.edu.cn+86 010-83572388

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026